Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production.

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage company focused on discovering and developing ground-breaking RNA-based therapeutics.

The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics addressing unmet needs in urology and oncology. This includes Versameb’s lead candidate VMB-100, a potentially first-in-class regenerative treatment for SUI, which is expected to enter clinical development in the second half of 2022.

Versameb’s proprietary VERSagile platform can both enhance the effectiveness of RNA and target multiple proteins simultaneously within a single molecule. Versameb will use Touchlight’s dbDNA technology for manufacturing and clinical supply of VMB-100 and other future pipeline products.

Touchlight’s dbDNA is a minimal, linear, double stranded, covalently closed DNA vector which is produced through an enzymatic manufacturing process. It can accommodate genes of interest of more than 20kb and is linearly scalable, making it highly adaptable to support a range of genetic medicines.

Karen Fallen, CEO, Touchlight DNA Services commented:

We are delighted to be supporting the experienced team at Versameb on the development of its product portfolio. dbDNA has shown superior yield and genetic stability compared to conventional plasmid methods in mRNA production as well as faster GMP manufacturing. Our advanced vector technology and enzymatic process will support the tremendous growth of mRNA technology as well as enabling other plasmid DNA reliant technologies to deliver beyond what is possible with current methods.

Klaas Zuideveld, CEO of Versameb, said:

We are excited to be driving the necessary activities to take our lead asset to the clinic in the shortest possible timeframe. Working with a company such as Touchlight and to utilise dbDNA as a starting material for the production of our mRNA therapeutics assures a production process which is innovative and gives a competitive advantage. The high stability, quality and speed offered by synthetic replication of DNA, the starting material for mRNA, plays as key role in the production of Versameb’s proprietary biologically optimized VERSagile mRNA pipeline.